Would you offer consolidative autologous stem cell transplant in CR1 for high risk diffuse large B-cell lymphoma (DLBCL)?

I would not routinely do so, as data do not support routine auto in CR1 for DLBCL outside of a clinical trial. There have been randomized trials evaluating auto in CR1 in patient populations in higher-risk IPI patients that have yielded mixed results, and collectively should be taken as not supporti...

Under no circumstances would I consolidate a CR1 patient with auto transplant.

The differences, if any, are so minimal, but carry long term consequences. With the available new therapies, one should not burn bridges by damaging the in vivo residual T- cells for possible use and harvest if the patie...

Thank you @Dr. First Last and @Dr. First Last for the response. I, too, am not in support of ASCT consolidation in high IPI and Double HIT Lymphoma in CR1, due lack of good data in favor of ASCT.